This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to timely regulatory approval of the Edwards SAPIEN transcatheter aortic heart valve; the timing and progress of clinical studies relating to the company's transcatheter valve technologies and the market opportunity for these products; the expected European launch of the Edwards SAPIEN valve and the anticipation of beginning sales in fourth quarter of 2007; and the market for transcatheter technologies. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2006.
Ascendra, Edwards, Edwards SAPIEN and RetroFlex are trademarks of
Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E
logo, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT,
PERIMOUNT Magna, and Swan-Ganz are trademarks of Edwards Lifesciences
Corporation and are reg
'/>"/>
| SOURCE Edwards Lifesciences Corporation Copyright©2007 PR Newswire. All rights reserved |